HD-6277 is a selective g-protein-coupled receptor 40 agonist developed by Hyundai Pharmaceutical to treat diabetes.[1][2]
References
edit- ^ Kim, Daehoon; Kim, Chun Hwa; Choi, Hyo Sun; Yang, Goeun; Kang, Seung Jun; Lee, Sun Hee; Lim, Kwan Soo; Park, Min Ah; Kim, Doo Young; Rhee, Jae Keol (1 July 2018). "HD-6277, a Novel GPR40 Agonist, Improves Glucose Homeostasis and Enhanced Glucose-Dependent Insulin Secretion in Beta Cells and Type 2 Diabetic Rats". Diabetes. 67 (Supplement_1). doi:10.2337/db18-1202-P. S2CID 91116872.
- ^ Kim, Ki-Hwan; Kim, Pan-Kyung; Yang, Hye-Jung (1 June 2019). "1179-P: Pharmacokinetics, Pharmacodynamics, and Safety of HD-6277, a Selective Agonist of G-Protein-Coupled Receptor 40, in Healthy Subjects as a First-in-Human Study". Diabetes. 68 (Supplement_1). doi:10.2337/db19-1179-P. S2CID 195427023.